YOLFTbeta
67

Gwo Xi Stem Cell Applied Technology Co. , Ltd

6704 · TWO · Healthcare / Biotechnology

19.45TWD-0.65 (-3.23%)

Price History

Full chart

Market Stats

Previous Close20.10
Open19.30
Day Range18.55 – 20.10
52-Week Range18.00 – 28.90
Volume65.20K
Market Cap2.62B
P/E (TTM)0.00
Forward P/E0.00
EPS-1.03
Dividend Yield0.00%
Beta0.10
50-Day Avg20.13
200-Day Avg22.00

About

Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke. The company is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the treatment of osteoarthritis; and GXIPC1, an allogeneic adipose-derived stem cells therapy in phase I clinical trials for use in the treatment of diabetes. The company was founded in 2011 and is based in Zhubei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOChuan-Feng Chiu
  • Employees55
  • HeadquartersNo. 2, Shengyi 3rd Road, Zhubei, Taiwan, 302041, Taiwan
  • Websitehttps://www.gwoxi.com.tw

Leadership

  • Chuan-Feng ChiuChief Executive Officer
  • Bangyu LIAccounting Supervisor
  • Mr. Po-Cheng LinChief Technology Officer

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue176.68M188.54M242.75M180.67M141.18M170.03M187.02M
Growth (%)-+6.71%+28.75%-25.58%-21.86%+20.44%+10.00%
Cost of Revenue55.89M21.49M45.68M25.86M44.40M53.38M55.05M
Gross Profit120.78M167.05M197.07M154.81M96.77M116.64M131.97M
Gross Margin68.36%88.60%81.18%85.69%68.55%68.60%70.56%
Operating Expense204.01M241.44M296.49M270.10M190.73M192.58M205.64M
Operating Income-83.23M-74.39M-99.42M-115.29M-93.95M-75.93M-73.67M
Operating Margin-47.11%-39.46%-40.96%-63.81%-66.55%-44.66%-39.39%
EBITDA-59.83M-44.17M-60.52M-49.94M-16.60M-13.81M-12.22M
EBITDA Margin-33.87%-23.43%-24.93%-27.64%-11.76%-8.12%-6.53%
Net Income-76.93M-84.20M-105.55M-112.11M-88.09M-83.32M-80.52M
Net Income Margin-43.54%-44.66%-43.48%-62.05%-62.40%-49.00%-43.05%
R&D93.15M86.83M95.11M109.16M108.17M110.67M115.50M
R&D as % of Total Revenue52.72%46.05%39.18%60.42%76.62%65.09%61.76%
Interest Expense1.16M1.34M1.67M1.96M12.36M11.43M9.83M
Interest Expense % of Total Revenue0.66%0.71%0.69%1.08%8.75%6.72%5.26%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.06B1.18B1.09B1.04B1.23B1.06B978.13M
Total Liabilities466.14M577.51M595.65M534.57M481.49M400.79M397.74M
Total Equity547.98M590.55M482.43M510.32M744.23M660.91M580.39M
Cash191.69M177.97M118.62M140.97M342.96M233.28M192.53M
Total Debt420.88M514.81M544.58M499.09M417.02M364.46M-
Net Debt229.19M340.38M425.96M358.12M74.05M131.18M128.59M

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-82.91M-72.56M-29.12M-64.19M-4.87M-52.28M-27.98M
Investing Cash Flow-220.45M-110.87M-43.17M-6.73M-33.07M-4.84M-
Financing Cash Flow191.90M169.71M12.93M93.27M239.95M-52.55M-
Capital Expenditure224.73M111.74M43.22M17.69M12.91M23.01M52.74M
Free Cash Flow-307.63M-184.29M-72.34M-81.88M-17.79M-75.30M-80.72M
FCF to OCF371.05%254.00%248.42%127.56%364.90%144.01%288.46%

Key Statistics & Ratios

Market Cap2.62B
Enterprise Value2.22B
Trailing P/E0.00
Forward P/E0.00
Price / Sales16.58
Price / Book2.98
EPS-1.03
Book Value7.79
Revenue (TTM)157.86M
Gross Profit (TTM)112.47M
EBITDA-37.49M
Profit Margin-62.74%
Operating Margin-76.68%
Return on Equity-14.43%
Return on Assets-5.41%
Shares Outstanding105.95M
Shares Float81.17M
Beta0.10
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%